文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

右美托咪定治疗非插管ICU患者活动亢进型谵妄:4D随机临床试验

Dexmedetomidine for treatment of hyperactive delirium in non-intubated ICU patients: the 4D randomized clinical trial.
PubMed 文献 · Intensive Care Med · 2025-10-29
一句话结论在非插管成人ICU活动亢进型谵妄患者中,右美托咪定较安慰剂显著缩短躁动持续时间中位数约1小时,并改善多终点联合模型结局。

4D试验为多中心、双盲、安慰剂对照、双臂、研究者发起的随机试验,在9个ICU纳入非插管成人活动亢进型谵妄患者,随机接受右美托咪定或安慰剂持续静脉输注至少36小时。主要终点为躁动持续时间、谵妄持续时间、需插管和深度镇静的多结局联合模型。最终分析151例,主要终点组间差异有统计学意义(中位差异-30分,95%CI -49至-12,P=0.001)。右美托咪定组躁动持续时间更短(1.0(1.0-2.0)小时 vs 2.0(1.0-7.0)小时,绝对差异95%CI -1.0(-2.0至-0.1);ES -0.60,95%CI -0.92至-0.27,P=0.001)。其他关键次要结局组间相似。

要点

  • 非插管成人ICU活动亢进型谵妄患者,右美托咪定持续静脉输注至少36小时,主要终点多结局联合模型组间差异有统计学意义(中位差异-30分,95%CI -49至-12,P=0.001)。
  • 右美托咪定组躁动持续时间中位数1.0(1.0-2.0)小时,安慰剂组2.0(1.0-7.0)小时,绝对差异95%CI -1.0(-2.0至-0.1),效应量-0.60(95%CI -0.92至-0.27,P=0.001)。
  • 其他关键次要结局(包括并发症如心动过缓或低血压、ICU住院时间或死亡)组间相似。
  • 研究在预计划中期分析时因有效性提前终止,最终分析纳入151例。

适用人群与场景

  • 非插管成人ICU活动亢进型谵妄患者,来自9个ICU。

处置流程与药物剂量

  • 右美托咪定或安慰剂持续静脉输注至少36小时。

研究设计与关键结果

  • 多中心、双盲、安慰剂对照、双臂、研究者发起的随机试验,在9个ICU纳入非插管成人活动亢进型谵妄患者,随机接受右美托咪定或安慰剂持续静脉输注至少36小时,主要终点为躁动持续时间、谵妄持续时间、需插管和深度镇静的多结局联合模型。
  • 入组时间为2017年12月至2022年2月,最终随访在2023年2月,研究在预计划中期分析时因有效性提前终止,最终分析纳入151例。
  • 主要终点组间差异有统计学意义(中位差异-30分,95%CI -49至-12,P=0.001)。
  • 右美托咪定组躁动持续时间1.0(1.0-2.0)小时 vs 安慰剂组2.0(1.0-7.0)小时,绝对差异95%CI -1.0(-2.0至-0.1);ES -0.60,95%CI -0.92至-0.27,P=0.001。
  • 其他关键次要结局(包括并发症如心动过缓或低血压、ICU住院时间或死亡)组间相似。

证据类型、等级与局限

  • 证据类型:多中心、双盲、安慰剂对照、双臂、研究者发起的随机试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在非插管成人ICU活动亢进型谵妄患者中,与安慰剂相比,右美托咪定在躁动控制、谵妄缓解及插管机械通气多终点联合模型上显示更大临床获益,作者认为右美托咪定似乎是一种有价值的替代选择,较安慰剂显著缩短躁动持续时间中位数约1小时。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Whether dexmedetomidine improves the control of hyperactive delirium in non-intubated intensive care unit (ICU) patients as compared with placebo remains uncertain.

METHODS: In a multicenter, double-blind, placebo-controlled, two-arm, investigator-initiated, randomized trial conducted in 9 ICUs, we randomly assigned non-intubated critically ill adults with hyperactive delirium to receive continuous intravenous infusion of dexmedetomidine or placebo for at least 36 h. The primary outcome was a joint modelling of multiple outcomes of agitation duration (score of + 1 or higher on the Richmond agitation-sedation scale), delirium duration, or the need for intubation and deep sedation. Key secondary outcomes included the occurrence of complications (such as bradycardia or hypotension), length of stay in ICU, or death.

RESULTS: Enrollment occurred from December 2017 to February 2022. Final follow-up was in February 2023. The study was stopped for efficacy at the time of the preplanned interim analysis. Among the 151 patients who were included in the final analysis, the between-group difference in the primary outcome was statistically significant (median difference, -30 points; 95% CI, - 49 to - 12, p = 0.001). Agitation duration was shorter in the dexmedetomidine group (1.0 (1.0-2.0) vs 2.0 (1.0-7.0) hours, absolute difference 95% CI - 1.0 (- 2.0 to - 0.1); ES, - 0.60; 95% CI, -0.92 to -0.27, p = 0.001). Other key secondary outcomes were similar between groups.

CONCLUSION: In non-intubated adult ICU patients with hyperactive delirium, the use of dexmedetomidine was associated with a greater clinical benefit than placebo for the joint modelling of multiple endpoints of agitation control, delirium resolution, and intubation with mechanical ventilation. Dexmedetomidine appears to be a valuable alternative that significantly reduced the median duration of agitation by approximately 1 h compared to placebo in hyperactive delirious non-intubated intensive care unit patients.

TRIAL REGISTRATION: ClinicalTrial.gov Identifier: NCT03317067. Registration on October 17th, 2017 prior to first patient inclusion. https://clinicaltrials.gov/search?term=NCT03317067 .

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Godet T, Louis C, Rieu B, et al. Dexmedetomidine for treatment of hyperactive delirium in non-intubated ICU patients: the 4D randomized clinical trial. Intensive Care Med. 2025. PMID: 41160116. doi:10.1007/s00134-025-08135-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。